Digital pill that tracks use when swallowed gets FDA approval


U.S. regulators approved the first medicine with an embedded sensor to help keep track of whether patients with mental illness are adhering to their prescriptions.

The decision marks a milestone in the convergence of technology and health care that also raises privacy concerns.

The so-called digital pill is a version of Otsuka Pharmaceutical Co.’s Abilify, which treats depression, bipolar disorder and schizophrenia. The sensor, developed by Proteus Digital Health, is activated by stomach fluids, sending a signal to a patch worn on the patient’s torso and transmitting the information to a smartphone app.

“This is the first time we’ll have an objective measurement of adherence,” said Kabir Nath, chief executive officer for North America at Otsuka Pharmaceutical. By allowing physicians to track a patient’s use, Nath said he hopes to avert “dramatic and immediate health-care crises, such as for schizophrenia patients where missing medicines can result in a psychotic break which will land them in an ER.”

The Food and Drug Administration’s approval comes as the technology sector increasingly turns to health care to test advances like machine learning, artificial intelligence and micro-electronics for everything from drug development to insurance.

“Being able to track ingestion of medications prescribed for mental illness may be useful for some patients,” Mitchell Mathis, director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research, said in a statement. Through an app, patients can also opt to report activity, rest and mood information to share with their caregiver, the companies said.

While many in the health industry are embracing new technology, others worry about protecting patient privacy as more data is generated and shared.

Patients who are prescribed the product, called Abilify MyCite, have to agree that their physicians can see the data. They can also choose whether or not to share information with caregivers, such as family members. Otsuka Pharmaceutical and certain insurers also plan to gather anonymized, aggregated data from patients who consent.

“We know some people don’t have relief of symptoms, and we don’t know if that’s just because they’re not taking their medication,” Nath said.

Otsuka Pharmaceutical, which is a unit of Tokyo-based Otsuka Holdings Co., plans to start the program with just a handful of health systems and gather evidence on the drug’s effects on adherence, he said.

Not all patients will appreciate such monitoring, says Lucia Savage, chief privacy and regulatory officer at Omada Health Inc., a startup focused on digital counseling programs for chronic conditions like diabetes.

“It creates a looking-over-your-shoulder effect,” Savage said.

Information about mental illness is particularly sensitive, said Savage, who previously was a privacy officer at the Department of Human and Health Services.

She suggested patients and their physicians ask questions like, “How is the data flowing? Where does the signal go? If it goes to somebody’s server, whose server is that? What are the business arrangements?”

Bob McQuade, Otsuka Pharmaceutical’s chief strategic officer, said patients will have a choice. The company will continue to sell regular Abilify, he said, and generic versions of the drug are available as well.

Closely held Proteus is based in Redwood City, California.



Reader Comments ...


Next Up in Lifestyle

High-salt diet could cause dementia, study finds
High-salt diet could cause dementia, study finds

Consuming too much salt can be dangerous for your health. It can cause your blood pressure and cholesterol to skyrocket, but it might also cause memory loss, according to a new report.  Researchers from Weill Cornell Medicine in New York recently conducted an experiment, published in the Nature Neuroscience journal, to determine if salt was...
Does ibuprofen cause infertility in men?
Does ibuprofen cause infertility in men?

A new study published in the Proceedings of the National Academy of Sciences of the United States seems to indicate that taking ibuprofen will lower the amount of testosterone a man produces. That might be true, but then people have taken  it one step farther to say that the decrease in testosterone leads to infertility. Dr. Lisa Hansard...
Want more bikes in Austin? So does Katie Smith Deolloz, Bike Austin’s new executive director
Want more bikes in Austin? So does Katie Smith Deolloz, Bike Austin’s new executive director

Bike Austin has named Katie Smith Deolloz its new executive director. Photo courtesy Bike Austin   Look for Katie Smith Deolloz riding a bike, walking or taking a bus, but don’t expect to see her driving a car. And now, look for her at the helm of Bike Austin. The non-profit organization, which promotes cycling for transportation...
17 things to keep the kids busy this weekend in Austin, Jan. 19-21
17 things to keep the kids busy this weekend in Austin, Jan. 19-21

Need some ideas for the weekend?  We have ideas that can keep kids busy. Know that Saturday is going to be beautiful, making it hard to believe we had a snow day earlier in the week. Sunday will be a great day for the rain boots. The Hill Country Science Mill will offer a predictable snow day on Saturday. Hill Country Science Mill...
Are you the cutest couple in Austin? Enter the 2018 Cutest Couples Contest
Are you the cutest couple in Austin? Enter the 2018 Cutest Couples Contest

Are your friends constantly telling you how cute you and your significant other are? Do they say, “Oh, gross” when you smooch at brunch? Do they tell you to “get a room” when you gaze at each other lovingly over happy hour beers? Do you think you’re pretty cute, too?  Let’s put it to the test. We&rsquo...
More Stories